Provesicles as Novel Drug Delivery Systems

被引:15
|
作者
Bayindir, Zerrin S. [1 ]
Yuksel, Nilufer [1 ]
机构
[1] Ankara Univ, Fac Pharm, Dept Pharmaceut Technol, TR-06100 Ankara, Turkey
关键词
Administration routes; characterization; provesicles; proliposomes; proniosomes; vesicular systems; IN-VIVO EVALUATION; ENHANCED INTESTINAL-ABSORPTION; MALTODEXTRIN-BASED PRONIOSOMES; NONIONIC SURFACTANT VESICLES; LOADED NEUTRAL PROLIPOSOMES; IMPROVED ORAL DELIVERY; VITRO SKIN PERMEATION; TRANSDERMAL DELIVERY; CANCER-THERAPY; BIOAVAILABILITY ENHANCEMENT;
D O I
10.2174/1389201016666150206101443
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Vesicular systems exhibit many attractive properties such as controlled drug release, ability to carry both hydrophilic and hydrophobic drugs, targetability and good biocompatibility. With these unique properties they can provide improved drug bioavailability and reduced side effects. Until now, many vesicular formulations have been studied in clinical and preclinical stages. Nevertheless, the major concern about these systems is their low physicochemical stability and high manufacturing expenses. The stability problems (fusion, aggregation, sedimentation, swelling, and drug leakage during storage) associated with the aqueous nature of vesicular systems hinders their effective usage. The advances on improving the stability of vesicular systems led to the emergence of provesicular systems, which are commonly described as dry, free flowing pre-formulations of vesicular drug delivery systems. Provesicles form vesicular systems upon hydratation with water and exhibit the advantages of vesicular systems with improved stability. The present article briefly reviews vesicular systems (particularly liposomes and niosomes) and enlightens about the innovations in the field. Overall investigations are reviewed and the provesicle approach is explained by giving detailed information on the composition, preparation, administration and characterization methods of provesicular systems (proliposomes and proniosomes). The scope of this article is expected to give insight to the researchers and industrialists to perform further research in this area.
引用
收藏
页码:344 / 364
页数:21
相关论文
共 50 条
  • [21] Advances in novel parentral drug delivery systems
    Patel, Rakesh
    Patel, Kaushal P.
    ASIAN JOURNAL OF PHARMACEUTICS, 2010, 4 (03) : 193 - 199
  • [22] Novel Drug Delivery Systems for the Treatment of Glaucoma
    Cara E. Capitena Young
    Malik Y. Kahook
    Leonard K. Seibold
    Current Ophthalmology Reports, 2019, 7 : 143 - 149
  • [23] Novel drug delivery systems for the treatment of glaucoma
    Vanrell, Rocio Herrero
    ACTA OPHTHALMOLOGICA, 2022, 100
  • [24] NOVEL DRUG-DELIVERY SYSTEMS FOR HYPERTENSION
    PRISANT, LM
    BOTTINI, B
    DIPIRO, JT
    CARR, AA
    AMERICAN JOURNAL OF MEDICINE, 1992, 93 : S45 - S55
  • [25] NOVEL DRUG DELIVERY SYSTEMS - CHIEN,YW
    SIVERLY, JR
    AMERICAN JOURNAL OF PHARMACEUTICAL EDUCATION, 1983, 47 (02) : 190 - 190
  • [26] Biomaterials, novel drug and cell delivery systems
    Langer, Robert
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2018, 256
  • [27] Novel drug delivery systems for steroidal hormones
    Lipp, R
    EXPERT OPINION ON THERAPEUTIC PATENTS, 2001, 11 (08) : 1291 - 1299
  • [28] Nanocapsules: The Weapons for Novel Drug Delivery Systems
    Kothamasu, Pavankumar
    Kanumur, Hemanth
    Ravur, Niranjan
    Maddu, Chiranjeevi
    Parasuramrajam, Radhika
    Thangavel, Sivakumar
    BIOIMPACTS, 2012, 2 (02) : 71 - 81
  • [29] Cyclodextrin based novel drug delivery systems
    Vyas, Amber
    Saraf, Shailendra
    Saraf, Swarnlata
    JOURNAL OF INCLUSION PHENOMENA AND MACROCYCLIC CHEMISTRY, 2008, 62 (1-2) : 23 - 42
  • [30] BIONANOTECHNOLOGY AND NOVEL TARGETED DRUG DELIVERY SYSTEMS
    Syed, Atif
    ANTICANCER RESEARCH, 2014, 34 (10) : 6192 - 6192